Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated September 05, 2025, titled "Glenmark Initiates a Multi-Country Phase 3 Clinical Trial for Envafolimab in Resectable Stage III Non-Small Cell Lung Cancer".
Press Release Sep 05 2025
Filed with NSE · · 3 pages · English
Summary by 6ix AI
The trial has received approval from the Drugs Controller General of India to begin patient enrollment and dosing in India. Clinical trial applications are also underway in Russia, Brazil, and Mexico to expand the study's reach.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Glenmark Pharmaceuticals Limited on 6ix
Earlier from Glenmark Pharmaceuticals
- Press Release Sep 02 2025
- Glenmark Pharmaceuticals Inc., USA to launch Eribulin Mesylate Injection, 1mg/2Ml (0.5 mg/mL) Single-Dose Vials
- FY 2024-25
- Q1FY 2025-26
- Press Release Aug 19 2025
Later from Glenmark Pharmaceuticals
- Hengrui Pharma and Glenmark Pharmaceuticals Enter Exclusive License Agreement for HER2 ADC Trastuzumab Rezetecan (SHR-A1811)
- Press Release Sep 24 2025
- Glenmark Pharmaceuticals Limited Press Release Oct 23 2025
- Glenmark Pharmaceuticals Inc., USA to launch Ropivacaine Hydrochloride Injection USP, 40 mg/20 mL (2mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL) Single-Dose Vials
- Glenmark Pharmaceuticals Limited Press Release Nov 04 2025
Follow Glenmark Pharmaceuticals into a list and get an email when it puts out news.
Follow Glenmark Pharmaceuticals